Mitoxantrone: An active agent in refractory non-Hodgkin's lymphomas

E. Bajetta, R. Buzzoni, P. Valagussa, G. Bonadonna

Research output: Contribution to journalArticle

Abstract

A phase II oriented study with mitoxantrone was undertaken in 31 patients with refractory non-Hodgkin's lymphomas (NHL); 30 patients had evaluable disease. The drug was administered through a 30-min intravenous infusion at the dose of 14 mg/m2 every 3 weeks. A minimum of two cycles were required to define treatment response. Twenty patients were previously treated with Adriamycin whose total dose was not exceeding 300 mg/m2. Complete response (CR) was documented in 9 patients, and partial response (PR), in 5 for a total response rate of 47% (14 of 30). Of 20 patients previously treated with Adriamycin, CR occurred in five and PR in two. The median time to progression was 3 months.Mitoxantrone was well tolerated, and no patient refused treatment. Mild leukopenia was evident in 10 patients and thrombocytopenia in 5 patients. In all cases, electrocardiograms (EKGs) was obtained before each treatment cycle. Systolic time intervals and left ventricular ejection fraction were repeated after 3 cycles and at the end of therapy. Laboratory tests failed to document any major cardiac abnormality. Mitoxantrone is an effective agent in refractory NHL and should be taken into consideration in the design of salvage regimens.

Original languageEnglish
Pages (from-to)100-103
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue number2
Publication statusPublished - 1988

Fingerprint

Mitoxantrone
Non-Hodgkin's Lymphoma
Doxorubicin
Electrocardiography
Systole
Leukopenia
Therapeutics
Intravenous Infusions
Thrombocytopenia
Stroke Volume

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mitoxantrone : An active agent in refractory non-Hodgkin's lymphomas. / Bajetta, E.; Buzzoni, R.; Valagussa, P.; Bonadonna, G.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 11, No. 2, 1988, p. 100-103.

Research output: Contribution to journalArticle

Bajetta, E, Buzzoni, R, Valagussa, P & Bonadonna, G 1988, 'Mitoxantrone: An active agent in refractory non-Hodgkin's lymphomas', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 11, no. 2, pp. 100-103.
Bajetta, E. ; Buzzoni, R. ; Valagussa, P. ; Bonadonna, G. / Mitoxantrone : An active agent in refractory non-Hodgkin's lymphomas. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1988 ; Vol. 11, No. 2. pp. 100-103.
@article{781dcd6c8f3f4abf80b13a7c7d3040c0,
title = "Mitoxantrone: An active agent in refractory non-Hodgkin's lymphomas",
abstract = "A phase II oriented study with mitoxantrone was undertaken in 31 patients with refractory non-Hodgkin's lymphomas (NHL); 30 patients had evaluable disease. The drug was administered through a 30-min intravenous infusion at the dose of 14 mg/m2 every 3 weeks. A minimum of two cycles were required to define treatment response. Twenty patients were previously treated with Adriamycin whose total dose was not exceeding 300 mg/m2. Complete response (CR) was documented in 9 patients, and partial response (PR), in 5 for a total response rate of 47{\%} (14 of 30). Of 20 patients previously treated with Adriamycin, CR occurred in five and PR in two. The median time to progression was 3 months.Mitoxantrone was well tolerated, and no patient refused treatment. Mild leukopenia was evident in 10 patients and thrombocytopenia in 5 patients. In all cases, electrocardiograms (EKGs) was obtained before each treatment cycle. Systolic time intervals and left ventricular ejection fraction were repeated after 3 cycles and at the end of therapy. Laboratory tests failed to document any major cardiac abnormality. Mitoxantrone is an effective agent in refractory NHL and should be taken into consideration in the design of salvage regimens.",
author = "E. Bajetta and R. Buzzoni and P. Valagussa and G. Bonadonna",
year = "1988",
language = "English",
volume = "11",
pages = "100--103",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Mitoxantrone

T2 - An active agent in refractory non-Hodgkin's lymphomas

AU - Bajetta, E.

AU - Buzzoni, R.

AU - Valagussa, P.

AU - Bonadonna, G.

PY - 1988

Y1 - 1988

N2 - A phase II oriented study with mitoxantrone was undertaken in 31 patients with refractory non-Hodgkin's lymphomas (NHL); 30 patients had evaluable disease. The drug was administered through a 30-min intravenous infusion at the dose of 14 mg/m2 every 3 weeks. A minimum of two cycles were required to define treatment response. Twenty patients were previously treated with Adriamycin whose total dose was not exceeding 300 mg/m2. Complete response (CR) was documented in 9 patients, and partial response (PR), in 5 for a total response rate of 47% (14 of 30). Of 20 patients previously treated with Adriamycin, CR occurred in five and PR in two. The median time to progression was 3 months.Mitoxantrone was well tolerated, and no patient refused treatment. Mild leukopenia was evident in 10 patients and thrombocytopenia in 5 patients. In all cases, electrocardiograms (EKGs) was obtained before each treatment cycle. Systolic time intervals and left ventricular ejection fraction were repeated after 3 cycles and at the end of therapy. Laboratory tests failed to document any major cardiac abnormality. Mitoxantrone is an effective agent in refractory NHL and should be taken into consideration in the design of salvage regimens.

AB - A phase II oriented study with mitoxantrone was undertaken in 31 patients with refractory non-Hodgkin's lymphomas (NHL); 30 patients had evaluable disease. The drug was administered through a 30-min intravenous infusion at the dose of 14 mg/m2 every 3 weeks. A minimum of two cycles were required to define treatment response. Twenty patients were previously treated with Adriamycin whose total dose was not exceeding 300 mg/m2. Complete response (CR) was documented in 9 patients, and partial response (PR), in 5 for a total response rate of 47% (14 of 30). Of 20 patients previously treated with Adriamycin, CR occurred in five and PR in two. The median time to progression was 3 months.Mitoxantrone was well tolerated, and no patient refused treatment. Mild leukopenia was evident in 10 patients and thrombocytopenia in 5 patients. In all cases, electrocardiograms (EKGs) was obtained before each treatment cycle. Systolic time intervals and left ventricular ejection fraction were repeated after 3 cycles and at the end of therapy. Laboratory tests failed to document any major cardiac abnormality. Mitoxantrone is an effective agent in refractory NHL and should be taken into consideration in the design of salvage regimens.

UR - http://www.scopus.com/inward/record.url?scp=0023893828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023893828&partnerID=8YFLogxK

M3 - Article

C2 - 3282421

AN - SCOPUS:0023893828

VL - 11

SP - 100

EP - 103

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -